Literature DB >> 1694826

Study of epitopes of cholera enterotoxin-related enterotoxins by checkerboard immunoblotting.

M Kazemi1, R A Finkelstein.   

Abstract

Checkerboard immunoblotting, a versatile new technique for examining multiple antigen and antibody interactions simultaneously, was applied in studies of epitopes in the cholera enterotoxin (CT)-related heat-labile enterotoxin (LT) family. The purified antigens used included the following: the B-subunit proteins from two CTs (CT-B-1 and CT-B-2), from classical and El Tor biotype strains of Vibrio cholerae, respectively; human LT-B-1 (H-LT-B-1) and porcine LT-B (P-LT-B) derived from LTs produced by Escherichia coli strains of human (H) and porcine (P) origins, respectively; and genetically engineered chimeric P-LT-Bs with amino acid substitutions from H-LT-B-1. The antigens were used in native, partially denatured, and CNBr-fragmented forms. The antisera included a variety of mouse monoclonal antibodies against these proteins as well as polyclonal hyperimmune sera and sera from adult American volunteer vaccinees or convalescents from induced cholera. Rabbit antisera against synthetic peptides of the CT-B-1 subunit were also used. In some instances, the effect of GM1 ganglioside on antibody binding was evaluated. The reactivity of the monoclonal antibodies was directed primarily against conformational epitopes: some were specific for homologous antigen; some were promiscuously reactive; and some recognized particular related proteins. Individual amino acids (most notably amino acid 46) exerted a dominant effect on epitope formation--in some instances, in a complementary fashion. Epitope expression was also affected by distant amino acid residues (polar effects). Some reactions were blocked by GM1 treatment of the immobilized antigen, indicating that the epitope was involved in or affected by GM1 binding. Polyclonal antibody responses varied within and among animal species. Human serum antitoxic responses were higher in convalescents from induced cholera than in recipients of a genetically engineered live vaccine, and the convalescent sera (from El Tor biotype cholera patients) generally preferred CT-B-2 to CT-B-1. The results demonstrate the potential significance of the differences among these immunologically related enterotoxins and may help provide direction to further vaccine development.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1694826      PMCID: PMC258819          DOI: 10.1128/iai.58.7.2352-2360.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  16 in total

1.  Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.

Authors:  M M Levine; J B Kaper; D Herrington; J Ketley; G Losonsky; C O Tacket; B Tall; S Cryz
Journal:  Lancet       Date:  1988-08-27       Impact factor: 79.321

2.  Checkerboard immunoblotting (CBIB): an efficient, rapid, and sensitive method of assaying multiple antigen/antibody cross-reactivities.

Authors:  M Kazemi; R A Finkelstein
Journal:  J Immunol Methods       Date:  1990-03-27       Impact factor: 2.303

3.  Facile identification of protein sequences by mass spectrometry. B subunit of Vibrio cholerae classical biotype Inaba 569B toxin.

Authors:  T Takao; H Watanabe; Y Shimonishi
Journal:  Eur J Biochem       Date:  1985-02-01

4.  Anti-idiotypic antibodies as probes of protein active sites: application to cholera toxin subunit B.

Authors:  D S Ludwig; R A Finkelstein; A E Karu; W S Dallas; E R Ashby; G K Schoolnik
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

5.  Monospecific equine antiserum against cholera exo-enterotoxin.

Authors:  R A Finkelstein
Journal:  Infect Immun       Date:  1970-12       Impact factor: 3.441

6.  Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up.

Authors:  J D Clemens; J R Harris; D A Sack; J Chakraborty; F Ahmed; B F Stanton; M U Khan; B A Kay; N Huda; M R Khan
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226

7.  Immunity to heat-labile enterotoxins of porcine and human Escherichia coli strains achieved with synthetic cholera toxin peptides.

Authors:  C O Jacob; R Arnon; R A Finkelstein
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

8.  Epitopes of the cholera family of enterotoxins.

Authors:  R A Finkelstein; M F Burks; A Zupan; W S Dallas; C O Jacob; D S Ludwig
Journal:  Rev Infect Dis       Date:  1987 May-Jun

9.  Immunological differences among the cholera/coli family of enterotoxins.

Authors:  B A Marchlewicz; R A Finkelstein
Journal:  Diagn Microbiol Infect Dis       Date:  1983-06       Impact factor: 2.803

10.  Pathogenesis of experimental cholera. Preparation and isolation of choleragen and choleragenoid.

Authors:  R A Finkelstein; J J LoSpalluto
Journal:  J Exp Med       Date:  1969-07-01       Impact factor: 14.307

View more
  8 in total

1.  Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin.

Authors:  R K Gupta; S C Szu; R A Finkelstein; J B Robbins
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

2.  Epitope mapping and characterization of antigenic determinants of heat-stable enterotoxin (STh) of enterotoxigenic Escherichia coli by using monoclonal antibodies.

Authors:  T Takeda; G B Nair; K Suzuki; H X Zhe; Y Yokoo; P De Mol; W Hemelhof; J P Butzler; Y Takeda; Y Shimonishi
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

3.  Use of automated sequencing of polymerase chain reaction-generated amplicons to identify three types of cholera toxin subunit B in Vibrio cholerae O1 strains.

Authors:  O Olsvik; J Wahlberg; B Petterson; M Uhlén; T Popovic; I K Wachsmuth; P I Fields
Journal:  J Clin Microbiol       Date:  1993-01       Impact factor: 5.948

4.  Construction and characterization of recombinant Vibrio cholerae strains producing inactive cholera toxin analogs.

Authors:  C C Häse; L S Thai; M Boesman-Finkelstein; V L Mar; W N Burnette; H R Kaslow; L A Stevens; J Moss; R A Finkelstein
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

5.  Monoclonal immunoglobulin A antibodies directed against cholera toxin prevent the toxin-induced chloride secretory response and block toxin binding to intestinal epithelial cells in vitro.

Authors:  F M Apter; W I Lencer; R A Finkelstein; J J Mekalanos; M R Neutra
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

6.  A nontoxic cholera enterotoxin (CT) analog is chimeric with regard to both epitypes of CT-B subunits, CT-B-1 and CT-B-2.

Authors:  M Boesman-Finkelstein; J W Peterson; L S Thai; R A Finkelstein
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

Review 7.  Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin.

Authors:  B D Spangler
Journal:  Microbiol Rev       Date:  1992-12

8.  Urea-induced release of heat-labile enterotoxin from Escherichia coli.

Authors:  Z H Qu; M Boesman-Finkelstein; R A Finkelstein
Journal:  J Clin Microbiol       Date:  1991-04       Impact factor: 5.948

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.